STRATA Skin Sciences (NASDAQ:SSKN) Stock Rating Upgraded by Zacks Investment Research

STRATA Skin Sciences (NASDAQ:SSKN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, “Strata Skin Sciences, Inc. is a medical technology company which focused on the dermatology market. Its products include the XTRAC laser(R) and VTRAC(R) excimer lamp systems for treatment of psoriasis, vitiligo and other skin conditions as well as the MelaFind (R) system used for identification and management of melanoma skin cancer. Strata Skin Sciences, Inc., formerly known as MELA Sciences, Inc., is based in Horsham, Pennsylvania. “

SSKN has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating on shares of STRATA Skin Sciences in a research note on Monday, September 16th. ValuEngine downgraded shares of STRATA Skin Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th. Finally, Oppenheimer assumed coverage on shares of STRATA Skin Sciences in a report on Wednesday, November 20th. They issued an “outperform” rating and a $7.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. STRATA Skin Sciences has an average rating of “Buy” and a consensus target price of $5.44.

STRATA Skin Sciences stock opened at $2.46 on Tuesday. The business’s 50-day simple moving average is $2.36 and its 200 day simple moving average is $2.30. STRATA Skin Sciences has a 12-month low of $1.65 and a 12-month high of $3.43. The company has a current ratio of 1.97, a quick ratio of 1.67 and a debt-to-equity ratio of 0.21.

STRATA Skin Sciences (NASDAQ:SSKN) last announced its quarterly earnings data on Monday, November 18th. The medical device company reported ($0.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.02). The firm had revenue of $7.48 million during the quarter, compared to analyst estimates of $9.12 million. STRATA Skin Sciences had a negative return on equity of 9.98% and a negative net margin of 9.74%. Equities research analysts forecast that STRATA Skin Sciences will post -0.1 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC grew its holdings in STRATA Skin Sciences by 35.2% during the second quarter. Acadian Asset Management LLC now owns 52,715 shares of the medical device company’s stock valued at $131,000 after purchasing an additional 13,716 shares during the period. Creative Planning boosted its position in shares of STRATA Skin Sciences by 42.9% during the second quarter. Creative Planning now owns 50,000 shares of the medical device company’s stock worth $125,000 after purchasing an additional 15,000 shares in the last quarter. BlackRock Inc. boosted its position in shares of STRATA Skin Sciences by 33.5% during the second quarter. BlackRock Inc. now owns 82,972 shares of the medical device company’s stock worth $207,000 after purchasing an additional 20,803 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of STRATA Skin Sciences by 3.5% during the second quarter. Vanguard Group Inc. now owns 627,003 shares of the medical device company’s stock worth $1,561,000 after purchasing an additional 21,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of STRATA Skin Sciences by 6.7% in the 2nd quarter. Renaissance Technologies LLC now owns 1,100,116 shares of the medical device company’s stock valued at $2,739,000 after buying an additional 69,300 shares during the period. 26.54% of the stock is owned by institutional investors and hedge funds.

STRATA Skin Sciences Company Profile

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

Featured Article: Hold Rating

Get a free copy of the Zacks research report on STRATA Skin Sciences (SSKN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.